Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04748172
Other study ID # 8121-21-SMC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date June 1, 2023

Study information

Verified date June 2023
Source Sheba Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .


Description:

Introduction: Although there is as yet no scientific evidence that a SARS-CoV-2 virus infection could have negative effects on fertility, currently the possibility that the virus could affect sperm function and egg performance cannot be excluded. Previous studies have already shown an association between influenza and infertility. SARS-CoV-2 seems to be far more aggressive in terms of severe illness, morbidity and mortality in comparison to common influenzas, thus it is reasonable to hypothesize a possible substantial effect of Covid-19 on fertility. At the cellular level, common influenza viruses promote oxidant-sensitive pathways, leading to increased oxidative stress. This mechanism has been blamed to cause male infertility through a reduction of progressive motility in spermatozoa and a simultaneous increase in sperm DNA fragmentation. Based on this pathogenic pathway, it can be hypothesized that SARS-CoV-2 could increase sperm DNA fragmentation, which might affect fertilizing potential. Along the same lines, SARS-CoV-2 may affect oocyte performance through mechanisms that increase oxidative stress. As SARS-CoV-2 acts through the angiotensin-converting enzyme 2 (ACE2) receptor, this was proposed as an additional pathway affecting ovaria follicles and oocytes. ACE2 receptors are expressed in human ovaries, while angiotensin has been detected in measurable amounts in the follicular fluid . Therefore, a possible negative impact of the virus through an interaction between the oocyte and the somatic cells cannot be ruled out. The COVID-19 pandemic exerted tremendous pressure on scientists to develop safe and effective vaccines. A few delivery systems for next-generation vaccines against COVID-19 were introduced. The new-generation vaccines include only a specific antigen or antigens of the pathogen, instead of the whole pathogen, thus providing a better safety profile. While SARS-CoV-2 has four main structural proteins, the spike protein (S) which is located at the outer surface of the virus particles and can bind to ACE2 on the cell surface and causes receptor-mediated endocytosis of the virus, is the main target to evoke the self-immune system. The mRNA vaccines represent the newest generation of vaccines in which all components can be engineered via chemical synthesis. Due to the mRNA molecules' low apparent transfection efficacy, lipid nanoparticles (LNPs) are often used to incorporate the mRNA molecules for transfection purposes. An additional advantage of the mRNA vaccine is that the antigen expression generated by the mRNA is a transient process and therefore the risk of host DNA integration is negligible. Furthermore, elimination of live materials poses an advantage from a quality control standpoint and allows quick product switching in manufacturing facilities. Since the process is fully-synthetic it also eliminates the risk of disease transmissions from the manufacturing facility. The effect of the systemic generation and introduction of just the S protein of the SARS-CoV-2 could have a negative influence on ovarian follicles and oocytes has not been studied yet. Anti Mullarian Hormone (AMH) is a glycoprotein produced by the granulosa cells of the antral follicles. Its circulating levels are associated with the fertility state of the ovary and in contrast to other hormones are not influenced by the state of the menstrual cycle. Therefore, AMH levels are considered the measurement of choice for estimating ovarian reserve. As Israel is the first country to widely vaccinate its population using the mRNA vaccines and due to all the aforementioned, the aim of this study is to evaluate the influence of the mRNA vaccines on ovarian reserve estimated by the change in AMH before and three-month following vaccination. Material and Methods: This is a prospective study including females that are planning to be vaccinated in Israel. Women will be asked to sign an informed consent to participate in the study while visiting the ambulatory vaccinating clinics before being vaccinated. Medical information will be collected by the research team during this visit using computerized questionnaire. Blood samples will be collected for AMH analysis before administration of the first mRNA vaccine shot. A follow up visit will be scheduled at three months after the first vaccination. During this visit, blood samples will be collected for AMH levels and for anti Covid-19 antibody levels (Serology). Additionally, women will be asked to complete a second computerized questionnaire which focused on possible adverse effects following vaccinations and gynecological well-being at 3,6 and 12 months from recruitment.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 11 Years to 42 Years
Eligibility Inclusion Criteria: - Age 11-42 - No previous exposure to Covid-19 vaccine (first or second dose) - No known past Covid-19 infection Exclusion Criteria: - Premature ovarian failure - Pregnancy - Fertility treatment - Past Covid-19 infection

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
SARS-CoV-2 virus vaccines
mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
Diagnostic Test:
AMH sampling
Blood sample for AMH on recruitment and after three months
anti Covid-19 antibody levels (Serology)
Blood sample for IgG against S1 protein after three months

Locations

Country Name City State
Israel Sheba Medical Center Ramat-Gan

Sponsors (1)

Lead Sponsor Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

References & Publications (12)

Agarwal A, Rana M, Qiu E, AlBunni H, Bui AD, Henkel R. Role of oxidative stress, infection and inflammation in male infertility. Andrologia. 2018 Dec;50(11):e13126. doi: 10.1111/and.13126. — View Citation

Anifandis G, Messini CI, Daponte A, Messinis IE. COVID-19 and fertility: a virtual reality. Reprod Biomed Online. 2020 Aug;41(2):157-159. doi: 10.1016/j.rbmo.2020.05.001. Epub 2020 May 8. — View Citation

Dutta S, Majzoub A, Agarwal A. Oxidative stress and sperm function: A systematic review on evaluation and management. Arab J Urol. 2019 Apr 24;17(2):87-97. doi: 10.1080/2090598X.2019.1599624. eCollection 2019. — View Citation

Homa ST, Vassiliou AM, Stone J, Killeen AP, Dawkins A, Xie J, Gould F, Ramsay JWA. A Comparison Between Two Assays for Measuring Seminal Oxidative Stress and their Relationship with Sperm DNA Fragmentation and Semen Parameters. Genes (Basel). 2019 Mar 19; — View Citation

Joguet G, Mansuy JM, Matusali G, Hamdi S, Walschaerts M, Pavili L, Guyomard S, Prisant N, Lamarre P, Dejucq-Rainsford N, Pasquier C, Bujan L. Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational stu — View Citation

Khomich OA, Kochetkov SN, Bartosch B, Ivanov AV. Redox Biology of Respiratory Viral Infections. Viruses. 2018 Jul 26;10(8):392. doi: 10.3390/v10080392. — View Citation

Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci. 2004 Nov;61(21):2738-43. doi: 10.1007/s00018-004-4242-5. — View Citation

Liu M, Chen F, Liu T, Chen F, Liu S, Yang J. The role of oxidative stress in influenza virus infection. Microbes Infect. 2017 Dec;19(12):580-586. doi: 10.1016/j.micinf.2017.08.008. Epub 2017 Sep 14. — View Citation

Percivalle E, Zavattoni M, Fausto F, Rovida F. Zika virus isolation from semen. New Microbiol. 2017 Jul;40(3):197-198. Epub 2017 May 17. — View Citation

Reis FM, Bouissou DR, Pereira VM, Camargos AF, dos Reis AM, Santos RA. Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fertil Steril. 2011 Jan;95(1):176-81. doi: 10.1016/j.fertnstert.2010 — View Citation

Vartak A, Sucheck SJ. Recent Advances in Subunit Vaccine Carriers. Vaccines (Basel). 2016 Apr 19;4(2):12. doi: 10.3390/vaccines4020012. — View Citation

Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. AAPS PharmSciTech. 2020 Aug 5;21(6):225. doi: 10.1208/s12249-020-01744-7. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Delta in AMH levels AMA levels on recruitment minos AMH levels after three months From first vaccination until the second AMH sampling - after three month
See also
  Status Clinical Trial Phase
Recruiting NCT06387498 - Testicular Tissue Cryopreservation (TTC) N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Recruiting NCT06043609 - Outcome Evaluation After Fertility Preservation
Not yet recruiting NCT05048771 - Fertility and Temporality in Pediatric Oncology
Completed NCT05368194 - Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins N/A
Recruiting NCT05176535 - Determination of Vaginal Colonization and the Effect of an Oral Probiotic (PROSALVAG) N/A
Recruiting NCT06360471 - Fertility Preservation and Pregnancy and Offspring Health Outcomes in Female Cancer
Recruiting NCT05271981 - Fertility After Uterine Artery Embolization
Recruiting NCT05815719 - Continuous Double Ovarian Stimulation. Phase 4
Recruiting NCT06127875 - Effects of Trying to Conceive Using an Home- or Hospital-based Ovulation Monitoring on Stress
Recruiting NCT05658848 - Effect of Collaborative Infertility Counseling on Coping Strategies and Marital Satisfaction N/A
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Completed NCT04396210 - Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
Completed NCT05134090 - Percutaneous Laparoscopy for Ovarian Tissue Cryopreservation.
Completed NCT05905289 - Survival and Reproductive Outcomes of Malignant Ovarian Germ Cell Tumors
Recruiting NCT05316467 - Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma Phase 2/Phase 3
Completed NCT04600869 - Effects of Naturalistic Decision-Making Model-based Oncofertility Care Education N/A
Withdrawn NCT04683237 - Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Not yet recruiting NCT06179420 - The Effectiveness of Advanced Decision Support Tool (OPT-IVF) for IVF Treatment